Literature DB >> 20658984

Proteolytic processing of tau.

Yipeng Wang1, Sarika Garg, Eva-Maria Mandelkow, Eckhard Mandelkow.   

Abstract

Tau aggregation is a hallmark of several neurodegenerative diseases, including AD (Alzheimer's disease), although the mechanism underlying tau aggregation remains unclear. Recent studies show that the proteolysis of tau plays an important role in both tau aggregation and neurodegeneration. On one hand, truncation of tau may generate amyloidogenic tau fragments that initiate the aggregation of tau, which in turn can cause toxicity. On the other hand, truncation of tau may result in tau fragments which induce neurodegeneration through unknown mechanisms, independently of tau aggregation. Blocking the truncation of tau thus may represent a promising therapeutic approach for AD or other tauopathies. In the present paper, we summarize our data on tau cleavage in a cell model of tauopathy and major results on tau cleavage reported in the literature.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20658984     DOI: 10.1042/BST0380955

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  51 in total

1.  Tyrosine nitration within the proline-rich region of Tau in Alzheimer's disease.

Authors:  Juan F Reyes; Yifan Fu; Laurel Vana; Nicholas M Kanaan; Lester I Binder
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Asparagine endopeptidase cleaves tau and promotes neurodegeneration.

Authors:  Hanna Rosenmann
Journal:  Nat Med       Date:  2014-11       Impact factor: 53.440

3.  The role of annealing and fragmentation in human tau aggregation dynamics.

Authors:  Carol J Huseby; Ralf Bundschuh; Jeff Kuret
Journal:  J Biol Chem       Date:  2019-02-11       Impact factor: 5.157

4.  Remodeling of the conformational ensemble of the repeat domain of tau by an aggregation enhancer.

Authors:  Elias Akoury; Marco D Mukrasch; Jacek Biernat; Katharina Tepper; Valery Ozenne; Eckhard Mandelkow; Martin Blackledge; Markus Zweckstetter
Journal:  Protein Sci       Date:  2016-03-24       Impact factor: 6.725

5.  Truncation of Tau selectively facilitates its pathological activities.

Authors:  Jianlan Gu; Wen Xu; Nana Jin; Longfei Li; Yan Zhou; Dandan Chu; Cheng-Xin Gong; Khalid Iqbal; Fei Liu
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

Review 6.  Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer's Disease.

Authors:  Cátia Janota; Cynthia A Lemere; Maria Alexandra Brito
Journal:  Mol Neurobiol       Date:  2015-07-05       Impact factor: 5.590

Review 7.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

Review 8.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

9.  Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels.

Authors:  Yoshinari Miyata; Xiaokai Li; Hsiu-Fang Lee; Umesh K Jinwal; Sharan R Srinivasan; Sandlin P Seguin; Zapporah T Young; Jeffrey L Brodsky; Chad A Dickey; Duxin Sun; Jason E Gestwicki
Journal:  ACS Chem Neurosci       Date:  2013-03-20       Impact factor: 4.418

Review 10.  Blood biomarkers for brain injury: What are we measuring?

Authors:  Keisuke Kawata; Charles Y Liu; Steven F Merkel; Servio H Ramirez; Ryan T Tierney; Dianne Langford
Journal:  Neurosci Biobehav Rev       Date:  2016-05-12       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.